Pfizer Advances Early-Stage Cancer Candidate PF-07994525, Extending Its Oncology Pipeline

Pfizer Inc (PFE) announced an update on their ongoing clinical study.

Pfizer Inc. (PFE) has launched a new early-stage cancer trial titled “An Open-Label Phase 1 Study to Evaluate PF-07994525 in Participants With Advanced Malignancies.” The study aims to test safety, drug exposure in the body, and early signs of tumor control in people with advanced cancers that no longer respond to standard treatment, a space with high unmet need.

The main treatment is PF-07994525, an oral experimental cancer drug given as a single-agent therapy. Midazolam, another oral drug, is used in a subset of patients to help Pfizer understand how PF-07994525 may affect the way other drugs are processed in the body.

The trial is interventional and Phase 1, which means it is focused on basic safety and dosing rather than clear proof of benefit. All patients get the study drug in a stepwise fashion, with no placebo and no blinding, so doctors and patients know what is being given and at what dose level.

Part 1 will increase doses to find a safe range and watch for early tumor responses in relapsed or refractory multiple myeloma and other advanced cancers. Part 2 will then add more patients at selected doses to build a better picture of safety, drug behavior, and initial anti-tumor signals.

The study was first submitted on 16 February 2026, signaling the formal start of the regulatory process and site setup. The latest update on 11 March 2026 confirms the trial remains in a “not yet recruiting” stage, so no human data are available yet and key completion dates are still ahead.

For investors, this update reinforces Pfizer’s push in oncology and early-stage pipeline building rather than near-term revenue. Positive safety and early activity data, once available, could support sentiment for PFE and help offset patent loss concerns, especially as it competes with oncology leaders like Bristol Myers Squibb and Johnson & Johnson.

As this Phase 1 trial is still starting up and has just been updated, the impact on valuation should be viewed as long term and option-like rather than a near-term catalyst. The study remains ongoing in setup with further details and future updates available on the ClinicalTrials portal.

To learn more about PFE’s potential, visit the Pfizer Inc drug pipeline page.